on Relief Therapeutics Holding SA (ETR:RLF)
MindMaze Therapeutics Presents 2026 Half-Year Results
MindMaze Therapeutics Holding SA released its 2026 half-year report on August 27, detailing key advancements and financial outcomes. The Geneva-based company, known for its precision neurotherapeutics, reported H1 revenue of CHF 0.5 million and a net loss of CHF 6.9 million.
The company expanded its U.S. reach by building its commercial organization and partnering with Vibra Healthcare. Real-world evidence from a multi-site program with Vibra demonstrated improved patient outcomes through intensive neurorehabilitation. In Europe, MindMaze advanced its reimbursement strategy and supported a University of Pittsburgh study exploring spinal cord stimulation for stroke recovery.
Additionally, the company simplified its organization by disposing of non-neurology operations and received CHF 4.0 million in equity financing. CEO Zach Henderson emphasized the focus on accelerating commercial adoption and enhancing strategic partnerships.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Relief Therapeutics Holding SA news